Диссертация (1140933), страница 22
Текст из файла (страница 22)
– 2000. – Vol. 355. –P. 1582-1587.138. Puddu P., Puddu G.M., Cravero E. et al. The relationship among hyperuricemia,endothelial dysfunction and cardiovascular diseases: molecular mechanism andclinical implications. // Journal of Cardiology. – 2012. – Vol. 59 (3). – P. 235-242.139. RamasubbuK.,DeswalA.,HerdejurgenC.etal.Aprospectiveechocardiographic evaluation of pulmonary hypertension in chronic hemodialysispatients in the United States: prevalence and clinical significance. // Int J Gen Med. –2010.
– Vol. 3. – P. 279–286.140. Ratto E., Leoncini G., Viazzi F. et al. C-reactive protein and target organ damagein untreated patients with primary hypertension. // J Am Soc Hypertens. – 2007ю –Vol. 1. – P. 407- 413.141. Rich S., Rabinovitch M. Diagnosis and treatment of secondary (non-category 1)pulmonary hypertension. // Circulationю – 2008. – Vol. 118.
– P. 2190–2199.142. Robert G. Fassett, Sree K. Venuthurupalli et al. Biomarkers in chronic kidneydisease: a review. // Kidney Int. – 2011. – Vol. 80 (8). – P. 806-821.143. Ronco C., Chionh C.Y., Haapio M. et al. The cardiorenal syndrome. // BloodPurif. – 2009. – Vol. 27 (1). – P. 114-126.144.
Ronco C., McCullough P., Anker S. et al. Cardio-renal syndromes: report fromthe consensus conference of the Acute Dialysis Quality Initiative. // Eur Heart J. –2010. – Vol. 31 (6). – P. 703–711.145. Sam F., Siwik D.A. Digesting the remodeled heart: role of lysosomal cysteineproteases in heart failure. // Hypertension. – 2006. – Vol. 48 (5). – P. 830–831.146. Sánchez-Lozada L.G., Tapia E., Santamaría J.
et al. Mild hyperuricemia inducesvasoconstriction and maintains glomerular hypertension in normal and remnantkidney rats. // Kidney Int. – 2005. – Vol. 67 (1). – P. 237–247.139147. Sandra N. Ofori, Osaretin J. Odia. Serum uric acid and target organ damage inessential hypertension. // Vascular Health and Risk Management. – 2014. – Vol.10. – P. 253–261.148. Sanjuan R., Oliva S.M., Blasco M.L. et al.
Plasma brain natriuretic peptide levelsin cardiac function assessment in chronic dialysis patients. // Cardiorenal Med. –2011. – Vol. 1. – P. 147–155.149. Sarnak M.J., Levey A.S., Schoolwerth A.C. et al. Kidney disease as risk factor fordevelopment of cardiovascular disease.
// Circulation. – 2003. – Vol. 108. – P. 21542169.150. Scardovi A.B., Coletta С., Aspromonte N. Brain natriuretic peptide plasma levelis a reliable indicator of advanced diastolic dysfunction in patients with chronic heartfailure. // Eur J Echocardiography. – 2007. – Vol. 8.
– Р. 30-36.151. Schiffrin E.L., Lipman M., Mann J.F.E. Chronic kidney disease. Effects on thecardiorenal system. // Circulation. – 2007. – Vol. 116 (1). – P. 85-97.152. Schoppet M., Shroff R.C., Hofbauer L.C., Shanahan C.M. Exploring the biologyof vascular calcification in chronic kidney disease: what’s circulating? // Kidney Int.– 2008.
– Vol. 73. – P. 384–390.153. Schrier R.W. Role of diminished renal function in cardiovascular mortality:marker or pathogenetic factor? // J Am Coll Cardiol. – 2006. – Vol. 47 (1). – P. 1–8.154. Shi B., Ni Z., Cai H. et al. High-sensitivity C-reactive protein: an independentrisk factor for left ventricular hypertrophy in patients with lupus nephritis. //J Biomed Biotechnol. – 2010. – Vol. 2010. – P. 373-426.155. Shlipak M.G., Fried L.F., Crump C. et al. Elevations of inflammatory andprocoagulant biomarkers in elderly persons with renal insufficiency.
// Circulation. –2003. – Vol. 107 (1). – P. 87–92.156. Shlipak M.G., Katz R., Sarnak M.J. et al. Cystatin C and prognosis forcardiovascular and kidney outcomes in elderly persons without chronic kidneydisease. // Ann Intern Med. – 2006. – Vol. 145 (4). – P. 237–246.140157. Shu-ichi Fujita, Okamoto Y., Shibata K. et al. Serum uric acid is associated withleft ventricular hypertrophy independent of serum parathyroid hormone in malecardiac patients.
// PLoS ONE. – 2013. – Vol. 8 (12). – P. e80223.158. Simonneau G., Robbins I.M., Beghetti M. et al. Updated clinical classification ofpulmonary hypertension. // J Am Coll Cardiol. – 2009. – Vol. 54 (1). – P. 43–54.159. Smilde T.D., Damman K., Navis G. et al. Differential associations between renalfunction and ‘‘modifiable’’ risk factors in patients with chronic heart failure. // ClinRes Cardiol.
– 2009. – Vol. 98 (2). – P. 121–129.160. Souza R., Jardim C., Fernandes C.J.C. et al. NT-proBNP as a tool to stratifydisease severity in pulmonary arterial hypertension. // Respiratory Medicine. –2007. – Vol. 101 (1). – P. 69–75.161. Spanaus K.S., Kollerits B., Ritz E. et al. Serum creatinine, cystatin C, and betatrace protein in diagnostic staging and predicting progression of primary nondiabeticchronic kidney disease.
// Clin Chem. – 2010. – Vol. 56 (5). – P. 740–749.162. Swaminathan S., Shah S.V. Novel inflammatory mechanisms of acceleratedatherosclerosis in kidney disease. // Kidney Int. – 2011. – Vol. 80 (5). – P. 453–463.163. Taddei S., Nami R., Bruno R.M. et al. Hypertension, left ventricular hypertrophyand chronic kidney disease. // Heart Fail Rev. – 2011.
– Vol. 16 (6). – P. 615-620.164. Tagore R., Ling L.H., Yang H. et al. Natriuretic peptides in chronic kidneydisease. // Clin. J. Am. Soc. Nephrol. – 2008. – Vol. 3 (6). – P. 1644–1651.165.Takami Y., Horio T., Iwashima Y. et al. Diagnostic and prognostic value ofplasma brain natriuretic peptide in non-dialysis-dependent CRF. // Am J KidneyDis. – 2004. – Vol.
44 (3). – P. 420–428.166. Takase H., Dohi Y., Toriyama T. et al. B-type natriuretic peptide levels andcardiovascular risk in patients with diastolic dysfunction on chronic haemodialysis:cross-sectional and observation studies. // Nephrol. Dial. Transplant. – 2011. – Vol.26. – P. 683–690.167. Tang W.H., Van Lente F., Shrestha K.
et al. Impact of myocardial function oncystatin C measurements in chronic systolic heart failure. // J Card Fail. – 2008. –Vol. 14 (5). – P. 394-399.141168. Thomas R., Kanso A., Sedor J.R. Chronic kidney disease and its complications.// Prim Care. – 2008.
– Vol. 35 (2). – P. 329-344.169. Tonelle C., Colle A., Fougereau M., Manuel Y. Partial amino acid sequence oftwo forms of human post-gamma globulin. // Biochemical Biophysical ResearchCommunications. – 1979. – Vol. 86 (3). – P. 613-619.170. Tschöpe С., Kasner М., Westermann D. et al. The role of NT-proBNP in thediagnostics of isolated diastolic dysfunction: correlation with echocardiographic andinvasive measurements. // European Heart Journal.
– 2005. – Vol. 26 (21). – Р.2277-2284.171. Tschöpe С., Kasner М., Westermann D. et al. Elevated NT-proBNP levels inpatients with dyspnea and increased left ventricular filling pressure during exercisedespite preserved systolic function. // J Card Fail. – 2005. – Vol. 11. – P. 28–33.172. Unal A., Sipahioglu M, .Oguz F. et al. Pulmonary hypertension in peritonealdialysis patients: prevalence and risk factors. // Perit Dial Int.
– 2009. – Vol. 29 (2). –P. 191-198.173. Unger T. The angiotensin type 2 receptor: variations on an anigmatic theme. //J Hypertens. – 1999. – Vol. 17. – P. 1775-1786.174. Vassale C., Andreassi M.G. Genetic polymorphism of the natriuretic peptidesystem in pathogenesis of cardiovascular disease: what lies on the horizon? // ClinChem. – 2009. – Vol. 55 (5). – P.
878–887.175. Vernooij J.W., Cramer M.J., Visseren F.L. et al. Relation between abdominalobesity, insulin resistance and left ventricular hypertrophy diagnosed byelectrocardiogram and magnetic resonance imaging in hypertensive patients. // Am JCardiol. – 2012. – Vol. 110. – P. 227–233.176. Viazzi F., Parodi D., Leoncini G. et al. Serum uric acid and target organ damagein primary hypertension. // Hypertension.
– 2005. – Vol. 45 (5). – P. 991–996.177. Wang A.Y., Lam C.W., Yu C.M. et al. N-terminal pro-brain natriuretic peptide:an independent risk predictor of cardiovascular congestion, mortality, and adversecardiovascular outcomes in chronic peritoneal dialysisNephrol. – 2007. – Vol. 18. – P.
321– 330.patients. // J Am Soc142178. Wang C.H., Li S.H., Weisel R.D. et al. C-reactive protein upregulates angiotensintype 1 receptors in vascular smooth muscle. // Circulation. – 2003. – Vol. 107 (13). –P. 1783-1790.179. Wang Z., Chesler N.C. Pulmonary vascular wall stiffness: an importantcontributor to the increased right ventricular afterload with pulmonary hypertension.// Pulm Circ. – 2011. – Vol. 1 (2). – P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
